Search Results - Mark G Lebwohl

  • Showing 1 - 15 results of 15
Refine Results
  1. 1

    Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses by Mark G. Lebwohl, April W. Armstrong, Andrew F. Alexis, Edward L. Lain, Abby A. Jacobson

    Published in Dermatology and Therapy (2024-09-01)
    Get full text
    Article


  2. 2

    Early Relief of Pruritus in Atopic Dermatitis with Crisaborole Ointment, A Non-steroidal, Phosphodiesterase 4 Inhibitor by Gil Yosipovitch, Linda F. Gold, Mark G. Lebwohl, Jonathan I. Silverberg, Anna M. Tallman, Lee T. Zane

    Published in Acta Dermato-Venereologica (2018-02-01)
    Get full text
    Article


  3. 3

    COVID-19 Vaccine-Induced Lichenoid Eruptions—Clinical and Histopathologic Spectrum in a Case Series of Fifteen Patients with Review of the Literature by Yonatan K. Sapadin, Elazar Mermelstein, Robert G. Phelps, Christopher F. Basler, JoAnn M. Tufariello, Mark G. Lebwohl

    Published in Vaccines (2023-02-01)
    Get full text
    Article


  4. 4

    Treatment switching and associated economic outcomes in patients with plaque psoriasis treated with biologics: A retrospective analysis of German claims data 2016−2021 by Andreas Pinter, Ahmed M. Soliman, Karina C. Manz, Valeria Weber, Paul Ludwig, Anja Mocek, Ariane Höer, Mark G. Lebwohl

    Published in JEADV Clinical Practice (2024-12-01)
    Get full text
    Article


  5. 5

    Current Treatments for Generalized Pustular Psoriasis: A Narrative Summary of a Systematic Literature Search by Lluís Puig, Hideki Fujita, Diamant Thaçi, Min Zheng, Ana Cristina Hernandez Daly, Craig Leonardi, Mark G. Lebwohl, Jonathan Barker

    Published in Dermatology and Therapy (2024-08-01)
    Get full text
    Article


  6. 6

    Treatment Discontinuation in Patients with Psoriasis Treated with Biologics: A Retrospective Analysis of German Health Claims Data by Andreas Pinter, Ahmed M. Soliman, Karina C. Manz, Valeria Weber, Paul Ludwig, Anja Mocek, Ariane Höer, Mark G. Lebwohl

    Published in Dermatology and Therapy (2024-05-01)
    Get full text
    Article


  7. 7

    Impact of Disease Factors of Patients with Psoriasis and Psoriatic Arthritis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry by Philip J. Mease, Andrew Blauvelt, Adam P. Sima, Silky W. Beaty, Robert Low, Braulio Gomez, Marie Gurrola, Mark G. Lebwohl

    Published in Dermatology and Therapy (2024-09-01)
    Get full text
    Article


  8. 8

    Correction: Biologics for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-analysis by Mark G. Lebwohl, André Carvalho, Akihiko Asahina, Jianzhong Zhang, Mir Sohail Fazeli, Ellen Kasireddy, Paul Serafini, Thomas Ferro, Ranga Gogineni, Diamant Thaçi

    Published in Dermatology and Therapy (2025-08-01)
    Get full text
    Article


  9. 9

    Biologics for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-analysis by Mark G. Lebwohl, André Carvalho, Akihiko Asahina, Jianzhong Zhang, Mir Sohail Fazeli, Ellen Kasireddy, Paul Serafini, Thomas Ferro, Ranga Gogineni, Diamant Thaçi

    Published in Dermatology and Therapy (2025-05-01)
    Get full text
    Article


  10. 10

    Brodalumab: 5-Year US Pharmacovigilance Report by Mark G. Lebwohl, John Y. Koo, April W. Armstrong, Bruce E. Strober, George M. Martin, Nicole N. Rawnsley, Earl L. Goehring, Abby A. Jacobson

    Published in Dermatology and Therapy (2024-05-01)
    Get full text
    Article


  11. 11

    Brodalumab: Seven-Year US Pharmacovigilance Report by Mark G. Lebwohl, John Y. Koo, April W. Armstrong, Bruce E. Strober, Soo Han Yoon, Nicole N. Rawnsley, Earl L. Goehring Jr., Abby A. Jacobson

    Published in Dermatology and Therapy (2025-07-01)
    Get full text
    Article


  12. 12

    Brodalumab: Six-Year US Pharmacovigilance Report by Mark G. Lebwohl, John Y. Koo, April W. Armstrong, Bruce E. Strober, Soo Han Yoon, Nicole N. Rawnsley, Earl L. Goehring, Gina D. Mangin, Abby A. Jacobson

    Published in Dermatology and Therapy (2024-11-01)
    Get full text
    Article


  13. 13

    Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis pre... by Hamida Turki, Akimichi Morita, Min Zheng, Tsen-Fang Tsai, Siew Eng Choon, Mark G Lebwohl, Slaheddine Marrakchi, A David Burden, Alexander A Navarini, Jinhua Xu, Sushmita Rajeswari, Hongjie Deng, Kay Tetzlaff, Christian Thoma, Hervé Bachelez

    Published in BMJ Open (2021-03-01)
    Get full text
    Article


  14. 14

    CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study by David M. Pariser, Mark G. Lebwohl, Janusz Jaworski, Jakub Trefler, Stefan Daniluk, Anna Dudek, Wojciech Baran, Witold Owczarek, Pawel Brzewski, Mariusz Sikora, Marek Krogulec, SungHyun Kim, JeeHye Suh, EunJin Choi, JungBin Cha, HyunJin Lee, SungJeong Lee, John Y. Koo

    Published in Dermatology and Therapy (2025-03-01)
    Get full text
    Article


  15. 15

    Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flares by James G. Krueger, Mrinal K. Sarkar, Mark G. Lebwohl, Akimichi Morita, Kenneth Gordon, Rachael Bogle, Christopher Cole, Anthony Coon, Richard G. Langley, Richard B. Warren, Arash Mostaghimi, Bruce Strober, A. David Burden, Min Zheng, Aaron R. Mangold, Milan J. Anadkat, Jonathan N. Barker, Joseph F. Merola, Lam C. Tsoi, Ming Tang, Kolja Becker, Denis Delic, Christian Thoma, Johann E. Gudjonsson

    Published in The Journal of Clinical Investigation (2025-09-01)
    Get full text
    Article


Search Tools: